Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19) has infected 86,4 M patients and resulted in 1,86 M deaths worldwide. Severe COVID-19 patients have elevated blood levels of interleukin-6 (IL-6), IL-1β, tumor necrosis factor (TNF)α, IL-8 and interferon (IFN)γ.
Objective: To investigate the effect of antiviral treatment serum cytokines in severe COVID-19 patients.
Methods: Blood was obtained from 29 patients (aged 32-79 yr) with laboratory-confirmed COVID-19 upon admission and 7 days after antiviral (Favipiravir or Lopinavir/Ritonavir) treatment. Patients also received standard supportive treatment in this retrospective observational study. Chest computed tomography (CT) scans were evaluated to investigate lung manifestations of COVID-19. Serum was also obtained and cytokines levels were evaluated. 19 age- and gender-matched healthy controls were studied.
Results: Anti-viral therapy significantly reduced CT scan scores and the elevated serum levels of C-reactive protein (CRP) and lactate dehydrogenase (LDH). In contrast, serum levels of IL-6, IL-8 and IFNγ were elevated at baseline in COVID-19 subjects compared to healthy subjects with IL-6 (p = 0.006) and IL-8 (p = 0.011) levels being further elevated after antiviral therapy. IL-1β (p = 0.01) and TNFα (p = 0.069) levels were also enhanced after treatment but baseline levels were similar to those of healthy controls. These changes occurred irrespective of whether patients were admitted to the intensive care unit.
Conclusion: Antiviral treatments did not suppress the inflammatory phase of COVID-19 after 7 days treatment although CT, CRP and LDH suggest a decline in lung inflammation. There was limited evidence for a viral-mediated cytokine storm in these COVID-19 subjects.
Keywords: COVID-19; Cytokines storm; Flow cytometry; SARS-CoV-2.
【저자키워드】 COVID-19, SARS-CoV-2, flow cytometry, Cytokines storm, 【초록키워드】 Treatment, coronavirus disease, severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, Necrosis, Tumor, antiviral therapy, Coronavirus disease 2019, Cytokine storm, coronavirus, therapy, Cytokines, Lopinavir/ritonavir, intensive care, severe COVID-19, Antiviral, IL-6, Lopinavir, Ritonavir, intensive care unit, interleukin-6, interferon, Favipiravir, lung, LDH, C-reactive protein, CRP, cytokine, Antiviral treatment, severe acute respiratory syndrome Coronavirus, lactate dehydrogenase, observational study, flow cytometry, Computed tomography, Chest computed tomography, serum, interleukin, tumor necrosis factor, CT scan, Patient, inflammatory phase, death, IL-8, age, Anti-viral therapy, change, Admission, IL-1β, Lactate, Evidence, Blood level, retrospective, Lung inflammation, Cytokines storm, COVID-19 patient, manifestation, Flow, C-reactive protein (CRP, tumor necrosis, blood levels, serum cytokines, acute respiratory syndrome, Supportive treatment, acute respiratory syndrome coronavirus, Serum level, Laboratory-confirmed COVID-19, subject, healthy control, healthy subjects, serum levels, IFNγ, severe COVID-19 patients, TNFα, healthy controls, serum cytokine, baseline levels, laboratory-confirmed, antiviral treatments, occurred, significantly, evaluated, elevated, reduced, subjects, cause, suppress, healthy subject, baseline level, was obtained, baseline, 【제목키워드】 Treatment, Kaletra, COVID-19 patient, cytokine level,